Online ISSN: 2515-8260

Keywords : adjuvants


Giant Cell Tumor Treatment by Curettage and Bone Cement in Proximal End of Tibia

Mohammed Basheer Wali, Elsayed Eletawy Soudy, Mohsen Fawzy Omar, Mohamed Ismael Kotb

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 4046-4054

Background: Surgical treatment stills the most effective treatment for a giant cell
tumor of bone (GCTB). The aim of the present study was to evaluate the outcomes
of surgical treatment of giant cell tumor in proximal end of tibia by curettage and
bone cement. Patients and methods: This clinical trial study was conducted on 18
patients underwent surgical treatment of giant cell tumor in proximal end of tibia
by curettage and bone cement at orthopedic department, Zagazig University
Hospitals. Their age was ranged from 22 to 41 years. Two thirds (66.7%) of the
studied group were females and one third (33.3%) of them were males (2:1). After
completion of the investigations, staging of the tumor was recorded using
Campanacci's radiological grading method. Postoperative follow up was done to
assess the functional outcome and to detect the presence of complications. Results:
The present study showed that, 83.3% had companaccis grade I and grade II
(16.7%). 88.8% underwent cement and hydrogen peroxide and 11.2%underwent
cement, hydrogen peroxide and internal fixation. Regarding MSTS, only 33.3% of
them had intermediate pain, all patients had enthused emotional acceptance and
66.7% had unlimited walking ability and 22.2% had intermediate gait. Post
operative follow up showed the recurrence rate was zero (0.0%) after a follow up
time (11.2±1.04) months ranged from 9 to12 months. There was only 11.1% of
patients had superficial infection. Conclusion: Surgical treatment of a giant cell
tumor of bone using Cement filling after extended curettage is provide a good
oncological outcome and joint preservation. Curettage with adjuvants is a feasible
first choice treatment option for GCTB with Cement filling does not increase the
recurrence rate.